FCP
ALNY icon

Fidelis Capital Partners’s Alnylam Pharmaceuticals ALNY Stock Holding History

Fidelis Capital Partners’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-563
Closed -$224K – 505
2025
Q4 		$224K Buy
563
+24
+4% +$10.6K 0.02% 450
2025
Q3 		$246K Buy
539
+3
+0.6% +$1.22K 0.02% 418
2025
Q2 		$229K Buy
+536
New +$148K 0.02% 397

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Fidelis Capital Partners's ALNY Position: Q1 2026 in Review

Fidelis Capital Partners sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2026, closing a stake of 563 shares — an estimated $224K sold.

Fidelis Capital Partners first reported a position in ALNY in Q2 2025 and held it in 3 quarters. The position peaked at $246K in Q3 2025. 793 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

  • Fidelis Capital Partners reported no remaining Alnylam Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Fidelis Capital Partners sold 563 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $224K.
  • Fidelis Capital Partners first reported a position in Alnylam Pharmaceuticals in Q2 2025 and held it in 3 quarters.
  • Fidelis Capital Partners's Alnylam Pharmaceuticals position peaked at $246K in Q3 2025.
  • 793 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Fidelis Capital Partners's 13F filing for Q1 2026, filed 6 May 2026.